Related Experiment Video
Updated: Dec 18, 2025

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
Published on: November 12, 2013
Neuroendocrine Targeting of Tissue Plasminogen Activator (t-PA)
Robert J Parmer1,2, Yun Gong3, Seung Hyun Yoo4
1Department of Medicine, University of California, USA.
Tissue plasminogen activator (t-PA) binds to Chromogranin A (CgA) within secretory vesicles. This interaction aids t-PA targeting and release from neuroendocrine cells, impacting plasminogen activation.
Area of Science:
- Neuroendocrinology
- Molecular Biology
- Biochemistry
Background:
- Tissue plasminogen activator (t-PA) is expressed in neuroendocrine cells, particularly chromaffin cells.
- t-PA is sorted into catecholamine storage vesicles and co-released with catecholamines.
- Chromogranin A (CgA) is crucial for targeting proteins to the regulated secretory pathway via granin complexes.
Purpose of the Study:
- To investigate the specific interaction between t-PA and CgA.
- To determine if this interaction is enhanced under trans-Golgi network (TGN) conditions.
- To elucidate the role of this interaction in t-PA targeting and release from neurosecretory cells.
Main Methods:
- Incubation of immobilized t-PA with iodinated CgA (¹²⁵I-CgA).
- Assessment of interaction specificity and saturation.
- Domain-specific interaction mapping using antibody and peptide competition studies.
Main Results:
- t-PA specifically and saturably interacted with CgA.
- The interaction was domain-specific, involving t-PA's EGF/finger and kringle 1 domains.
- A specific hydrophilic domain within CgA mediated the interaction.
Conclusions:
- t-PA interacts with CgA, likely facilitated by aggregated granin complexes.
- This interaction may be critical for targeting t-PA into secretory vesicles and its subsequent release.
- Findings have implications for understanding plasminogen activation in physiological and pathological states like cerebral ischemia.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Clot Retraction and Fibrinolysis
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

